SCHEMBL3299100

SCHEMBL3299100

Cc1cc(Nc2ccnc(Nc3ccc(C(=O)N4CCC(NC(C)c5cccnc5)CC4)cc3)n2)ccc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 12/20 0.47
CDK2 P24941 12/20 0.47
IKBKB O14920 2/20 0.40
CHUK O15111 2/20 0.40
IKBKG Q9Y6K9 2/20 0.40
PTK2 Q05397 1/20 0.40
IRAK4 Q9NWZ3 2/20 0.40
AURKA O14965 2/20 0.40
MAP4K4 O95819 1/20 0.40
PIM1 P11309 1/20 0.40
MAPK8 P45983 1/20 0.40
GSK3B P49841 1/20 0.40
AURKB Q96GD4 1/20 0.40
HIPK2 Q9H2X6 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
MEN1 O00255 1/20 0.39
RECQL P46063 1/20 0.39
BLM P54132 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3301247 0.93 CDK2 (0.47) CDK1CDK2IKBKBCHUKIKBKG
SCHEMBL3301332 0.92 CDK2 (0.48) CDK1CDK2IKBKBCHUKIKBKG
SCHEMBL3301383 0.89 CDK2 (0.42) CDK1CDK2IKBKBCHUKIKBKG
SCHEMBL3299991 0.89 MAPK8 (0.43) CDK1CDK2IKBKBCHUKIKBKG
SCHEMBL3301841 0.89 CDK2 (0.47) CDK1CDK2IKBKBCHUKIKBKG
SCHEMBL3299553 0.88 CDK2 (0.45) CDK1CDK2IKBKBCHUKIKBKG
SCHEMBL3298130 0.87 CDK2 (0.43) CDK1CDK2IKBKBCHUKIKBKG
SCHEMBL3301045 0.87 CDK2 (0.46) CDK1CDK2IKBKBCHUKIKBKG
SCHEMBL3301949 0.87 CDK2 (0.44) CDK1CDK2IKBKBCHUKIKBKG
SCHEMBL3302815 0.86 CDK1 (0.42) CDK1CDK2IKBKBCHUKIKBKG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2010-04-15 US disclosed
WO-2009056693-A1 NOVEL DERIVATIVES OF N, N'- 2, 4-DIANILINOPYRIMIDINES, PREPARATION THEREOF AS MEDICAMENTS PHARMACEUTICAL COMPOSITIONS AND IN PARTICULAR AS IKK INHIBITORS SANOFI-AVENTIS (FR) 2009-05-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100093668-A1 N,N'-2,4-DIANILINOPYRIMIDINE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS ESSENTIALLY AS IKK INHIBITORS CHUK, IKBKB, IKBKE CDK1 15/4885CDK2 8/4885IKBKB 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.